SCHEMBL3474566

SCHEMBL3474566

O=C(NC(O)C1CCCCCC1)c1cc(-n2ncc(=O)n(CC(O)COCc3ccccc3)c2=O)ccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 10/20 0.55
CTSS P25774 1/20 0.36
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3474036 0.90 P2RX7 (0.59) P2RX7POLB
SCHEMBL3473604 0.88 P2RX7 (0.69) P2RX7TSHR
SCHEMBL3473050 0.88 P2RX7 (0.69) P2RX7TSHR
SCHEMBL5168922 0.88 P2RX7 (0.69) P2RX7TSHR
SCHEMBL3475210 0.88 P2RX7 (0.69) P2RX7TSHR
SCHEMBL3475597 0.88 P2RX7 (0.50) P2RX7ALDH1A1
SCHEMBL3476181 0.87 P2RX7 (0.60) P2RX7TSHR
SCHEMBL3472378 0.87 P2RX7 (0.68) P2RX7TSHR
SCHEMBL4995938 0.87 P2RX7 (0.57) P2RX7
SCHEMBL3473561 0.86 P2RX7 (0.56) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671053-B2 Benzamide inhibitors of the P2X7 receptor PFIZER, INC. (US) 2010-03-02 US disclosed
US-20090042886-A1 Benzamide Inhibitors of the P2X7 Receptor PFIZER, INC. (US) 2009-02-12 US disclosed
US-7407956-B2 Benzamide inhibitors of the P2X7 receptor PFIZER, INC. (US) 2008-08-05 US disclosed
US-20070281939-A1 Benzamide Inhibitors of The P2X7 Receptor PFIZER INC. 2007-12-06 US disclosed
US-7235657-B2 Methods for preparing P2X7 inhibitors PFIZER INC. (US) 2007-06-26 US disclosed
EP-1763353-A1 COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR Warner-Lambert Company LLC (US) 2007-03-21 EP disclosed
US-7176202-B2 Benzamide inhibitors of the P2X7 receptor PFIZER INC. (US) 2007-02-13 US disclosed
US-20060040939-A1 Benzamide inhibitors of the P2X, receptor DOMBROSKI MARK A 2006-02-23 US disclosed
US-20060018904-A1 Combination therapies utilizing benzamide inhibitors of the P2X7 receptor WARNER-LAMBERT COMPANY LLC 2006-01-26 US disclosed
WO-2006003517-A1 COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR WARNER-LAMBERT COMPANY LLC (US) 2006-01-12 WO disclosed
US-20050288256-A1 Methods for preparing P2X7 inhibitors PFIZER INC. 2005-12-29 US disclosed
US-20050288288-A1 Methods for preparing P2X7 inhibitors PFIZER INC. 2005-12-29 US disclosed
US-6974812-B2 Benzamide inhibitors of the P2X7 Ereceptor PFIZER INC. (US) 2005-12-13 US disclosed
EP-1581232-A1 3-(3,5-DIOXO-4,5-DIHYDRO-3H-(1,2,4)TRIAZIN-2-YL)-BENZAMIDE DERIVATIVES AS P2X7-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Pfizer Products Inc. (US) 2005-10-05 EP disclosed
US-20040180894-A1 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis) PFIZER INC. 2004-09-16 US disclosed
WO-2004058270-A1 3-(3,5-DIOXO-4,5-DIHYDRO-3H-(1,2,4)TRIAZIN-2-YL)-BENZAMIDE DERIVATIVES AS P2X7-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES PFIZER PRODUCTS INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042886-A1 Benzamide Inhibitors of the P2X7 Receptor IL1R1, P2RY1, P2RX1 P2RX7 7/4885CTSS 1425/4885POLB 4165/4885
US-20040180894-A1 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis) IL1R1, P2RY1, P2RX7 P2RX7 3/4885CTSS 2152/4885POLB 3492/4885
US-20060018904-A1 Combination therapies utilizing benzamide inhibitors of the P2X7 receptor CSF3R, CSF1R, IL1R1 P2RX7 72/4885CTSS 969/4885POLB 4841/4885
US-20050288256-A1 Methods for preparing P2X7 inhibitors P2RX7, P2RX1, P2RX3 P2RX7 1/4885CTSS 1886/4885POLB 4546/4885
US-20070281939-A1 Benzamide Inhibitors of The P2X7 Receptor IL1R1, P2RY1, P2RX1 P2RX7 7/4885CTSS 1425/4885POLB 4165/4885
US-20050288288-A1 Methods for preparing P2X7 inhibitors P2RX7, P2RX1, P2RX2 P2RX7 1/4885CTSS 2493/4885POLB 4148/4885
US-20060040939-A1 Benzamide inhibitors of the P2X, receptor IL1R1, P2RX1, P2RX3 P2RX7 7/4885CTSS 1572/4885POLB 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.